France Clears Path for Europe's First Biofungicide

French regulators approved Amoéba's AXPERA biofungicide, opening the door to EU-wide rollout with distributor Koppert.

1 Jul 2026

France's health and safety agency, ANSES, has granted marketing authorization to Amoéba's AXPERA biofungicide, a decision the company describes as Europe's first long-term regulatory approval for a biocontrol product of its kind. Issued on July 1, the ruling positions France as rapporteur Member State, meaning other EU countries can now move forward with their own approvals under existing national procedures. Years of regulatory work led to this juncture, and a commercial launch phase long anticipated by the agricultural sector can now begin.

Koppert, Amoéba's distribution partner, will bring AXPERA to market under two brand names. TIAGAN will serve vineyard applications, while YAZU is designated for vegetable crops throughout the EU. The authorization spans 15 years, and AXPERA carries no maximum residue limits, a distinction that officials suggested could appeal strongly to growers facing tightening food-safety rules. Jean-Baptiste Eberst, Amoéba's regulatory affairs director, called it "the very first long-term authorization of our biocontrol product in Europe."

Because biofungicides have often struggled against fragmented, country-by-country approval timelines, a 15-year French authorization stands out. Analysts said the length and residue-free status of the approval reflect unusual confidence in the underlying technology. For vineyard and vegetable growers across the bloc, the practical effect will depend on how quickly individual member states complete their own reviews.

Yet the significance extends beyond Europe. Amoéba and Koppert have already tested AXPERA in strategic-crop trials in Brazil, according to company statements, suggesting the product's commercial ambitions reach well past the continent where it just secured its first foothold. Demand for residue-free crop protection has grown alongside stricter limits on conventional fungicides, a trend that could work in AXPERA's favor as national approvals accumulate.

Whether that momentum converts into sustained market share remains to be seen. Still, with distribution infrastructure already established and regulatory groundwork largely complete, AXPERA appears further along than many comparable biocontrol products at this stage. The coming rollout across EU member states could offer an early test of how quickly residue-free alternatives can scale.